A Study of Baricitinib for Delaying Type 1 Diabetes
Phase 3
150
about 5.5 years
1–35
7 sites in FL, IA, KY +2
What this study is about
Researchers are testing if baricitinib can delay the onset of type 1 diabetes in people at high risk. The trial will last up to five years and involve approximately 150 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Baricitinib
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
baricitinib
oral (Oral Tablet)
Secondary: Change from Baseline in AUC Ratio (AUC C-peptide/AUC Glucose × 1000), Change from Baseline in Body Mass Index (BMI) Percentile, Change from Baseline in Glucose AUC, Change from Baseline in Glucose-Stimulated C-peptide Area Under the Curve (AUC), Change from Baseline in Height, Change from Baseline in Matsuda Index, Change from Baseline in Short Form 36 Version 2 Health Survey, Acute (SF-36v2), PK: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib
Endocrinology